

AMENDMENT TO THE CLAIMS

Please amend the claims without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows.

In the Claims:

1. (Currently amended) A monolayer bioadhesive pharmaceutical dosage form which can be administered nasally and is in film form, comprising a at least one lidocaine containing layer based on crosslinked hydrophilic polymers from 30% by weight to 60% by weight of lidocaine, based on the total amount of crosslinked hydrophilic polymers,

wherein the dosage form has a tear strength of at least 40 N and

the hydrophilic polymer of the active ingredient-containing layer has been crosslinked in situ and the ratio of hydrophilic polymers to crosslinker is from 2:1 to 5:1 by weight and wherein the active ingredient-containing layer has a concentration gradient from about 8% 50% by weight to about 60% 50% by weight of lidocaine; and

wherein the lidocaine-containing layer is also an adhesive layer.

2. (Previously presented) The dosage form as claimed in claim 1, characterized in that the dosage form has a tear strength, of at least 50 N.

3. (Previously presented) The dosage form as claimed in claim 1, characterized in that a cellulose ether has been used as hydrophilic polymer.

4. (Previously presented) The dosage form as claimed in claim 1, characterized in that the dosage form has a tear strength of at least 60 N.

5. (Previously presented) The dosage form as claimed in claim 1, characterized in that the dosage form exhibits controlled release of lidocaine.

6. (Previously presented) ~~The dosage form as claimed in claim 1, characterized in that the dosage form is monolayer or multilayer.~~

7. (Previously presented) — The dosage form as claimed in claim 6, characterized in that the dosage form has at least one active ingredient containing layer, one covering layer and/or one adhesive layer.

8. (Original) — The dosage form as claimed in claim 7, characterized in that one active ingredient containing layer is the adhesive layer.

9. (Previously presented) — The dosage form as claimed in claim 7, characterized in that the covering layer is impermeable for the active ingredient.

10. (Previously presented) A method for controlling primary headaches in humans which comprises of administering a therapeutically effective amount of the bioadhesive pharmaceutical dosage form of claim 1.

11. (Previously presented) The method of claim 10, wherein the control of primary headaches is via controlling neurovascular pain.

12. (Previously presented) The method of claim 10, wherein the control of primary headaches is reduces the effect of a migraine.

13. (Previously presented) The dosage form as claimed in claim 3, characterized in that the cellulose ether is selected from the group consisting of hydroxyethylcellulose, methylcellulose, hydroxypropylcellulose and hydroxypropylmethylcellulose.

14. (Previously presented) The dosage form as claimed in claim 4, characterized in that the hydrophilic polymer is a cellulose ether and the cellulose ether is selected from the group consisting of hydroxyethylcellulose, methylcellulose, hydroxypropylcellulose and hydroxypropylmethylcellulose.